Company Event • 07 Nov 2026 05:00 • Upcoming
Add To Calendar
Q3 2026
Company Event • 01 Oct 2026 20:30 • Latest
Study result
Company Event • 07 Aug 2026 04:00 • Upcoming
Add To Calendar
Q2 2026
No more events
𝛼SK or SearchENTITY
AgomAb Therapeutics (AGMB US)
AgomAb Therapeutics (AGMB US)
9
Analysis
Health Care • Belgium
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications. The company's pipeline includes small molecule and antibody product candidates, such as Ontunisertib (AGMB-129) for Crohn's disease and AGMB-447 for idiopathic pulmonary fibrosis. AgomAb Therapeutics was founded in 2017 and is headquartered in Antwerp, Belgium.
morex